Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease.

Dieter BP, Meek RL, Anderberg RJ, Cooney SK, Bergin JL, Zhang H, Nair V, Kretzler M, Brosius FC, Tuttle KR.

PLoS One. 2019 Feb 14;14(2):e0211555. doi: 10.1371/journal.pone.0211555. eCollection 2019.

2.

Mitochondrial uncoupling has no effect on microvascular complications in type 2 diabetes.

Hinder LM, Sas KM, O'Brien PD, Backus C, Kayampilly P, Hayes JM, Lin CM, Zhang H, Shanmugam S, Rumora AE, Abcouwer SF, Brosius FC 3rd, Pennathur S, Feldman EL.

Sci Rep. 2019 Jan 29;9(1):881. doi: 10.1038/s41598-018-37376-y.

3.

Soluble ST2 and Galectin-3 and Progression of CKD.

Alam ML, Katz R, Bellovich KA, Bhat ZY, Brosius FC, de Boer IH, Gadegbeku CA, Gipson DS, Hawkins JJ, Himmelfarb J, Kestenbaum BR, Kretzler M, Robinson-Cohen C, Steigerwalt SP, Tuegel C, Bansal N.

Kidney Int Rep. 2018 Sep 21;4(1):103-111. doi: 10.1016/j.ekir.2018.09.013. eCollection 2019 Jan.

4.

Consent for Genetic Biobanking in a Diverse Multisite CKD Cohort.

Troost JP, Hawkins J, Jenkins DR, Gipson DS, Kretzler M, El Shamy O, Bellovich K, Perumal K, Bhat Z, Massengill S, Steigerwalt S, Pennathur S, Brosius FC, Gadegbeku CA; Michigan O’Brien Kidney Translational Research Center.

Kidney Int Rep. 2018 Jun 12;3(6):1267-1275. doi: 10.1016/j.ekir.2018.06.002. eCollection 2018 Nov.

5.

Myeloperoxidase-derived oxidants damage artery wall proteins in an animal model of chronic kidney disease-accelerated atherosclerosis.

Zeng L, Mathew AV, Byun J, Atkins KB, Brosius FC 3rd, Pennathur S.

J Biol Chem. 2018 May 11;293(19):7238-7249. doi: 10.1074/jbc.RA117.000559. Epub 2018 Mar 26.

6.

The Promise of Systems Biology for Diabetic Kidney Disease.

Brosius FC, Ju W.

Adv Chronic Kidney Dis. 2018 Mar;25(2):202-213. doi: 10.1053/j.ackd.2017.10.012. Review.

7.

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.

Tuttle KR, Brosius FC 3rd, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Tanaka Y, Haneda M, Liu J, Silk ME, Cardillo TE, Duffin KL, Haas JV, Macias WL, Nunes FP, Janes JM.

Nephrol Dial Transplant. 2018 Nov 1;33(11):1950-1959. doi: 10.1093/ndt/gfx377.

8.

Shared and distinct lipid-lipid interactions in plasma and affected tissues in a diabetic mouse model.

Sas KM, Lin J, Rajendiran TM, Soni T, Nair V, Hinder LM, Jagadish HV, Gardner TW, Abcouwer SF, Brosius FC 3rd, Feldman EL, Kretzler M, Michailidis G, Pennathur S.

J Lipid Res. 2018 Feb;59(2):173-183. doi: 10.1194/jlr.M077222. Epub 2017 Dec 13.

9.

ABIN1 Determines Severity of Glomerulonephritis via Activation of Intrinsic Glomerular Inflammation.

Korte EA, Caster DJ, Barati MT, Tan M, Zheng S, Berthier CC, Brosius FC 3rd, Vieyra MB, Sheehan RM, Kosiewicz M, Wysoczynski M, Gaffney PM, Salant DJ, McLeish KR, Powell DW.

Am J Pathol. 2017 Dec;187(12):2799-2810. doi: 10.1016/j.ajpath.2017.08.018. Epub 2017 Sep 19.

10.

Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice.

Zhang H, Nair V, Saha J, Atkins KB, Hodgin JB, Saunders TL, Myers MG Jr, Werner T, Kretzler M, Brosius FC.

Kidney Int. 2017 Oct;92(4):909-921. doi: 10.1016/j.kint.2017.03.027. Epub 2017 May 26.

11.

Dual CCR2/CCR5 antagonist treatment attenuates adipose inflammation, but not microvascular complications in ob/ob mice.

O'Brien PD, Hinder LM, Parlee SD, Hayes JM, Backus C, Zhang H, Ma L, Sakowski SA, Brosius FC 3rd, Feldman EL.

Diabetes Obes Metab. 2017 Oct;19(10):1468-1472. doi: 10.1111/dom.12950. Epub 2017 Jun 2.

12.

Comparative RNA-Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease.

Hinder LM, Park M, Rumora AE, Hur J, Eichinger F, Pennathur S, Kretzler M, Brosius FC 3rd, Feldman EL.

J Cell Mol Med. 2017 Sep;21(9):2140-2152. doi: 10.1111/jcmm.13136. Epub 2017 Mar 8.

13.

Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications.

Sas KM, Kayampilly P, Byun J, Nair V, Hinder LM, Hur J, Zhang H, Lin C, Qi NR, Michailidis G, Groop PH, Nelson RG, Darshi M, Sharma K, Schelling JR, Sedor JR, Pop-Busui R, Weinberg JM, Soleimanpour SA, Abcouwer SF, Gardner TW, Burant CF, Feldman EL, Kretzler M, Brosius FC 3rd, Pennathur S.

JCI Insight. 2016 Sep 22;1(15):e86976. doi: 10.1172/jci.insight.86976.

14.

JAK inhibition in the treatment of diabetic kidney disease.

Brosius FC, Tuttle KR, Kretzler M.

Diabetologia. 2016 Aug;59(8):1624-7. doi: 10.1007/s00125-016-4021-5. Epub 2016 Jun 22. Review.

15.

Cardiovascular autonomic neuropathy associates with nephropathy lesions in American Indians with type 2 diabetes.

Wheelock KM, Jaiswal M, Martin CL, Fufaa GD, Weil EJ, Lemley KV, Yee B, Feldman E, Brosius FC 3rd, Knowler WC, Nelson RG, Pop-Busui R.

J Diabetes Complications. 2016 Jul;30(5):873-9. doi: 10.1016/j.jdiacomp.2016.03.008. Epub 2016 Mar 11.

16.

Transcriptional networks of murine diabetic peripheral neuropathy and nephropathy: common and distinct gene expression patterns.

Hur J, O'Brien PD, Nair V, Hinder LM, McGregor BA, Jagadish HV, Kretzler M, Brosius FC 3rd, Feldman EL.

Diabetologia. 2016 Jun;59(6):1297-306. doi: 10.1007/s00125-016-3913-8. Epub 2016 Mar 21.

17.

Structural Predictors of Loss of Renal Function in American Indians with Type 2 Diabetes.

Fufaa GD, Weil EJ, Lemley KV, Knowler WC, Brosius FC 3rd, Yee B, Mauer M, Nelson RG.

Clin J Am Soc Nephrol. 2016 Feb 5;11(2):254-61. doi: 10.2215/CJN.05760515. Epub 2016 Jan 20.

18.

Targeted Lipidomic and Transcriptomic Analysis Identifies Dysregulated Renal Ceramide Metabolism in a Mouse Model of Diabetic Kidney Disease.

Sas KM, Nair V, Byun J, Kayampilly P, Zhang H, Saha J, Brosius FC 3rd, Kretzler M, Pennathur S.

J Proteomics Bioinform. 2015 Oct;Suppl 14. pii: 002. Epub 2015 May 18.

19.

Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker.

Ju W, Nair V, Smith S, Zhu L, Shedden K, Song PXK, Mariani LH, Eichinger FH, Berthier CC, Randolph A, Lai JY, Zhou Y, Hawkins JJ, Bitzer M, Sampson MG, Thier M, Solier C, Duran-Pacheco GC, Duchateau-Nguyen G, Essioux L, Schott B, Formentini I, Magnone MC, Bobadilla M, Cohen CD, Bagnasco SM, Barisoni L, Lv J, Zhang H, Wang HY, Brosius FC, Gadegbeku CA, Kretzler M; ERCB, C-PROBE, NEPTUNE, and PKU-IgAN Consortium.

Sci Transl Med. 2015 Dec 2;7(316):316ra193. doi: 10.1126/scitranslmed.aac7071.

20.

Prevention of lithium-associated renal failure: recent evidence.

Davis JM, Rosenbaum A, Shahinian V, Brosius FC.

Lancet Psychiatry. 2015 Dec;2(12):1045-7. doi: 10.1016/S2215-0366(15)00498-8. No abstract available.

PMID:
26613842
21.

The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes.

Hur J, Dauch JR, Hinder LM, Hayes JM, Backus C, Pennathur S, Kretzler M, Brosius FC 3rd, Feldman EL.

Diabetes. 2015 Sep;64(9):3294-304. doi: 10.2337/db15-0133. Epub 2015 May 15.

22.

Maintenance of GLUT4 expression in smooth muscle prevents hypertension-induced changes in vascular reactivity.

Atkins KB, Seki Y, Saha J, Eichinger F, Charron MJ, Brosius FC.

Physiol Rep. 2015 Feb 12;3(2). pii: e12299. doi: 10.14814/phy2.12299. Print 2015 Feb 1.

23.

JAK inhibition and progressive kidney disease.

Brosius FC 3rd, He JC.

Curr Opin Nephrol Hypertens. 2015 Jan;24(1):88-95. doi: 10.1097/MNH.0000000000000079. Review.

24.

MicroRNA-21 in glomerular injury.

Lai JY, Luo J, O'Connor C, Jing X, Nair V, Ju W, Randolph A, Ben-Dov IZ, Matar RN, Briskin D, Zavadil J, Nelson RG, Tuschl T, Brosius FC 3rd, Kretzler M, Bitzer M.

J Am Soc Nephrol. 2015 Apr;26(4):805-16. doi: 10.1681/ASN.2013121274. Epub 2014 Aug 21.

25.

Research capacity. Enabling the genomic revolution in Africa.

H3Africa Consortium, Rotimi C, Abayomi A, Abimiku A, Adabayeri VM, Adebamowo C, Adebiyi E, Ademola AD, Adeyemo A, Adu D, Affolabi D, Agongo G, Ajayi S, Akarolo-Anthony S, Akinyemi R, Akpalu A, Alberts M, Alonso Betancourt O, Alzohairy AM, Ameni G, Amodu O, Anabwani G, Andersen K, Arogundade F, Arulogun O, Asogun D, Bakare R, Balde N, Baniecki ML, Beiswanger C, Benkahla A, Bethke L, Boehnke M, Boima V, Brandful J, Brooks AI, Brosius FC, Brown C, Bucheton B, Burke DT, Burnett BG, Carrington-Lawrence S, Carstens N, Chisi J, Christoffels A, Cooper R, Cordell H, Crowther N, Croxton T, de Vries J, Derr L, Donkor P, Doumbia S, Duncanson A, Ekem I, El Sayed A, Engel ME, Enyaru JC, Everett D, Fadlelmola FM, Fakunle E, Fischbeck KH, Fischer A, Folarin O, Gamieldien J, Garry RF, Gaseitsiwe S, Gbadegesin R, Ghansah A, Giovanni M, Goesbeck P, Gomez-Olive FX, Grant DS, Grewal R, Guyer M, Hanchard NA, Happi CT, Hazelhurst S, Hennig BJ, Hertz- C, Fowler, Hide W, Hilderbrandt F, Hugo-Hamman C, Ibrahim ME, James R, Jaufeerally-Fakim Y, Jenkins C, Jentsch U, Jiang PP, Joloba M, Jongeneel V, Joubert F, Kader M, Kahn K, Kaleebu P, Kapiga SH, Kassim SK, Kasvosve I, Kayondo J, Keavney B, Kekitiinwa A, Khan SH, Kimmel P, King MC, Kleta R, Koffi M, Kopp J, Kretzler M, Kumuthini J, Kyobe S, Kyobutungi C, Lackland DT, Lacourciere KA, Landouré G, Lawlor R, Lehner T, Lesosky M, Levitt N, Littler K, Lombard Z, Loring JF, Lyantagaye S, Macleod A, Madden EB, Mahomva CR, Makani J, Mamven M, Marape M, Mardon G, Marshall P, Martin DP, Masiga D, Mason R, Mate-Kole M, Matovu E, Mayige M, Mayosi BM, Mbanya JC, McCurdy SA, McCarthy MI, McIlleron H, Mc'Ligeyo SO, Merle C, Mocumbi AO, Mondo C, Moran JV, Motala A, Moxey-Mims M, Mpoloka WS, Msefula CL, Mthiyane T, Mulder N, Mulugeta Gh, Mumba D, Musuku J, Nagdee M, Nash O, Ndiaye D, Nguyen AQ, Nicol M, Nkomazana O, Norris S, Nsangi B, Nyarko A, Nyirenda M, Obe E, Obiakor R, Oduro A, Ofori-Acquah SF, Ogah O, Ogendo S, Ohene-Frempong K, Ojo A, Olanrewaju T, Oli J, Osafo C, Ouwe Missi Oukem-Boyer O, Ovbiagele B, Owen A, Owolabi MO, Owolabi L, Owusu-Dabo E, Pare G, Parekh R, Patterton HG, Penno MB, Peterson J, Pieper R, Plange-Rhule J, Pollak M, Puzak J, Ramesar RS, Ramsay M, Rasooly R, Reddy S, Sabeti PC, Sagoe K, Salako T, Samassékou O, Sandhu MS, Sankoh O, Sarfo FS, Sarr M, Shaboodien G, Sidibe I, Simo G, Simuunza M, Smeeth L, Sobngwi E, Soodyall H, Sorgho H, Sow Bah O, Srinivasan S, Stein DJ, Susser ES, Swanepoel C, Tangwa G, Tareila A, Tastan Bishop O, Tayo B, Tiffin N, Tinto H, Tobin E, Tollman SM, Traoré M, Treadwell MJ, Troyer J, Tsimako-Johnstone M, Tukei V, Ulasi I, Ulenga N, van Rooyen B, Wachinou AP, Waddy SP, Wade A, Wayengera M, Whitworth J, Wideroff L, Winkler CA, Winnicki S, Wonkam A, Yewondwos M, sen T, Yozwiak N, Zar H.

Science. 2014 Jun 20;344(6190):1346-8. doi: 10.1126/science.1251546. No abstract available.

26.

Podocytes, signaling pathways, and vascular factors in diabetic kidney disease.

Brosius FC, Coward RJ.

Adv Chronic Kidney Dis. 2014 May;21(3):304-10. doi: 10.1053/j.ackd.2014.03.011. Review.

27.

Podocyte-specific GLUT4-deficient mice have fewer and larger podocytes and are protected from diabetic nephropathy.

Guzman J, Jauregui AN, Merscher-Gomez S, Maiguel D, Muresan C, Mitrofanova A, Diez-Sampedro A, Szust J, Yoo TH, Villarreal R, Pedigo C, Molano RD, Johnson K, Kahn B, Hartleben B, Huber TB, Saha J, Burke GW 3rd, Abel ED, Brosius FC, Fornoni A.

Diabetes. 2014 Feb;63(2):701-14. doi: 10.2337/db13-0752. Epub 2013 Oct 7.

28.

How to find a prognostic biomarker for progressive diabetic nephropathy.

Brosius FC, Pennathur S.

Kidney Int. 2013 Jun;83(6):996-8. doi: 10.1038/ki.2013.58.

29.

New targets for treatment of diabetic nephropathy: what we have learned from animal models.

Brosius FC 3rd, Alpers CE.

Curr Opin Nephrol Hypertens. 2013 Jan;22(1):17-25. doi: 10.1097/MNH.0b013e32835b3766. Review.

30.

Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli.

Hodgin JB, Nair V, Zhang H, Randolph A, Harris RC, Nelson RG, Weil EJ, Cavalcoli JD, Patel JM, Brosius FC 3rd, Kretzler M.

Diabetes. 2013 Jan;62(1):299-308. doi: 10.2337/db11-1667. Epub 2012 Nov 8.

31.

Perspectives on systems biology applications in diabetic kidney disease.

Komorowsky CV, Brosius FC 3rd, Pennathur S, Kretzler M.

J Cardiovasc Transl Res. 2012 Aug;5(4):491-508. doi: 10.1007/s12265-012-9382-7. Epub 2012 Jun 26. Review.

32.

Smooth muscle protein 22 alpha-Cre is expressed in myeloid cells in mice.

Shen Z, Li C, Frieler RA, Gerasimova AS, Lee SJ, Wu J, Wang MM, Lumeng CN, Brosius FC 3rd, Duan SZ, Mortensen RM.

Biochem Biophys Res Commun. 2012 Jun 15;422(4):639-42. doi: 10.1016/j.bbrc.2012.05.041. Epub 2012 May 16.

33.

Do we now have a prognostic biomarker for progressive diabetic nephropathy?

Brosius FC, Saran R.

J Am Soc Nephrol. 2012 Mar;23(3):376-7. doi: 10.1681/ASN.2012010090. Epub 2012 Feb 9. No abstract available.

34.

GLUT1 enhances mTOR activity independently of TSC2 and AMPK.

Buller CL, Heilig CW, Brosius FC 3rd.

Am J Physiol Renal Physiol. 2011 Sep;301(3):F588-96. doi: 10.1152/ajprenal.00472.2010. Epub 2011 May 25.

35.
36.

Understanding kidney disease: toward the integration of regulatory networks across species.

Ju W, Brosius FC 3rd.

Semin Nephrol. 2010 Sep;30(5):512-9. doi: 10.1016/j.semnephrol.2010.07.008. Review.

37.

Susceptible mice: identifying a diabetic nephropathy disease locus using a murine model.

Brosius FC.

Kidney Int. 2010 Sep;78(5):431-2. doi: 10.1038/ki.2010.199.

38.

A new pair of SOCS for diabetic nephropathy.

Brosius FC 3rd, Banes-Berceli A.

J Am Soc Nephrol. 2010 May;21(5):723-4. doi: 10.1681/ASN.2010030286. Epub 2010 Apr 22. No abstract available.

39.

Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.

Duan SZ, Usher MG, Foley EL 4th, Milstone DS, Brosius FC 3rd, Mortensen RM.

Diabetologia. 2010 Jul;53(7):1493-505. doi: 10.1007/s00125-010-1748-2. Epub 2010 Apr 17. Erratum in: Diabetologia. 2012 Jan;55(1):270-1.

40.

Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice.

Zhang H, Schin M, Saha J, Burke K, Holzman LB, Filipiak W, Saunders T, Xiang M, Heilig CW, Brosius FC 3rd.

Am J Physiol Renal Physiol. 2010 Jul;299(1):F91-8. doi: 10.1152/ajprenal.00021.2010. Epub 2010 Apr 7.

41.

Abnormalities in signaling pathways in diabetic nephropathy.

Brosius FC, Khoury CC, Buller CL, Chen S.

Expert Rev Endocrinol Metab. 2010;5(1):51-64.

42.

The management of diabetic neuropathy in CKD.

Pop-Busui R, Roberts L, Pennathur S, Kretzler M, Brosius FC, Feldman EL.

Am J Kidney Dis. 2010 Feb;55(2):365-85. doi: 10.1053/j.ajkd.2009.10.050. Epub 2009 Dec 30. Review. No abstract available.

43.

Mouse models of diabetic nephropathy.

Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, Levi M, McIndoe RA, Sharma K, Smithies O, Susztak K, Takahashi N, Takahashi T; Animal Models of Diabetic Complications Consortium.

J Am Soc Nephrol. 2009 Dec;20(12):2503-12. doi: 10.1681/ASN.2009070721. Epub 2009 Sep 3. Review.

44.

The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.

Zhao W, Thacker SG, Hodgin JB, Zhang H, Wang JH, Park JL, Randolph A, Somers EC, Pennathur S, Kretzler M, Brosius FC 3rd, Kaplan MJ.

J Immunol. 2009 Aug 15;183(4):2729-40. doi: 10.4049/jimmunol.0804341. Epub 2009 Jul 20.

45.

GLUT1-induced cFLIP expression promotes proliferation and prevents apoptosis in vascular smooth muscle cells.

Vesely ED, Heilig CW, Brosius FC 3rd.

Am J Physiol Cell Physiol. 2009 Sep;297(3):C759-65. doi: 10.1152/ajpcell.00213.2009. Epub 2009 Jul 8.

46.

A rapid, PPAR-gamma-dependent effect of pioglitazone on the phosphorylation of MYPT.

Atkins KB, Irey B, Xiang N, Brosius FC 3rd.

Am J Physiol Cell Physiol. 2009 May;296(5):C1151-61. doi: 10.1152/ajpcell.00343.2008. Epub 2009 Mar 4.

47.

Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy.

Berthier CC, Zhang H, Schin M, Henger A, Nelson RG, Yee B, Boucherot A, Neusser MA, Cohen CD, Carter-Su C, Argetsinger LS, Rastaldi MP, Brosius FC, Kretzler M.

Diabetes. 2009 Feb;58(2):469-77. doi: 10.2337/db08-1328. Epub 2008 Nov 18.

48.

Is the ER stressed out in diabetic kidney disease?

Brosius FC 3rd, Kaufman RJ.

J Am Soc Nephrol. 2008 Nov;19(11):2040-2. doi: 10.1681/ASN.2008090959. Epub 2008 Oct 8. No abstract available.

49.

New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy.

Brosius FC 3rd.

Rev Endocr Metab Disord. 2008 Dec;9(4):245-54. doi: 10.1007/s11154-008-9100-6. Review.

50.

Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.

Zhang H, Saha J, Byun J, Schin M, Lorenz M, Kennedy RT, Kretzler M, Feldman EL, Pennathur S, Brosius FC 3rd.

Am J Physiol Renal Physiol. 2008 Oct;295(4):F1071-81. doi: 10.1152/ajprenal.90208.2008. Epub 2008 Jul 30.

Supplemental Content

Loading ...
Support Center